SEC Form 4 · accession 0001144204-15-067600
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Monica E. Luchi
Officer — EVP & CMO
Period of report
Nov 19, 2015
Accepted (ET)
Nov 23, 2015 · 6:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $0.98 | Nov 19, 2015 | A | 400,000 | A | — | Nov 19, 2025 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1The stock options shall vest over a period of three years, with 1/3 of the options vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the following two-year period.
- F2The stock options were granted as an inducement grant pursuant to NASDAQ Listing Rule 5635(c)(4) in connection with the reporting person's appointment as EVP, Global Drug Development and Chief Medical Officer.